Preferred Label : Tagtociclib;
NCIt synonyms : Cyclin-dependent Kinase 2 Inhibitor PF-07104091; CDK2 Inhibitor PF-07104091; (1R,3S)-3-(3-(3-(Methoxymethyl)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-5-yl)cyclopentyl
isopropylcarbamate;
NCIt definition : An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential
antineoplastic activity. Upon administration, tagtociclib selectively targets, binds
to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction
of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine
kinases that are important regulators of cell cycle progression and cellular proliferation
and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important
role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle
transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase
and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.;
UNII : XBD0JF5EHJ;
CAS number : 2460249-19-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2460249-19-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : PF 07104091; PF-07104091;
NCI Metathesaurus CUI : CL1412749;
Origin ID : C175251;
UMLS CUI : C5446373;
Semantic type(s)
- concept_is_in_subset
- has_target
